Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Long-Term Outcome of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) Using an Enhancer-Deleted Self-Inactivating Gammaretroviral Vector

Blood (2022) 140 (Supplement 1): 10643–10645.

https://doi.org/10.1182/blood-2022-159768

Published: 2022

Journal Articles

Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein-Barr Virus-Positive (EBV + ) Leiomyosarcomas (LMS)

Lauren S Jiménez-Kurlander, Gerald Behr, Nancy J Bunin, Ekaterina Doubrovina, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Leo Mascarenhas, Sarah Nikiforow, Richard J O'Reilly, Anita Price, Barry Shulkin, Ashok Srinivasan, Stephanie Suser, Justin Wahlstrom, Baodong Xing, Susan Prockop

Blood (2022) 140 (Supplement 1): 7524–7526.

https://doi.org/10.1182/blood-2022-157765

Published: 2022

Journal Articles

New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV + PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Kris Michael Mahadeo, Robert A. Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Norma Guzman-Becerra, Manher Joshi, Aditi Mehta, Sarah Nikiforow, Ran Reshef, Wei Ye, Susan Prockop

Blood (2022) 140 (Supplement 1): 10374–10376.

https://doi.org/10.1182/blood-2022-157766

Published: 2022

Journal Articles

Lentiviral Gene Therapy with Low Dose Conditioning for X-Linked SCID Results in Complete Immune Reconstitution and No Evidence of Clonal Expansion

Blood (2022) 140 (Supplement 1): 7770–7771.

https://doi.org/10.1182/blood-2022-159979

Published: 2022

Journal Articles

Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant

Blood (2022) 139 (18): 2758–2769.

https://doi.org/10.1182/blood.2021014255

Published: 2022

Includes: Supplemental data

Journal Articles

Interim Results of a Pilot, Prospective, Randomized, Double-Blinded, Vehicle- and Comparator-Controlled Trial on Safety and Efficacy of a Topical Inhibitor of Janus Kinase 1/2 (Ruxolitinib INCB018424 Phosphate 1.5% Cream) for Non-Sclerotic and Superficially Sclerotic Chronic Cutaneous Graft-Versus-Host Disease

Alina Markova, Alexander Pan, Stephen Dusza, Arifa Chowdhury, Oluwaseun Kukoyi, Miguel-Angel Perales, Mario Lacouture, Susan Prockop, Doris M Ponce

Blood (2021) 138 (Supplement 1): 3915.

https://doi.org/10.1182/blood-2021-144743

Published: 2021

Journal Articles

Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant

Susan Prockop, Laurence Gamelin, Rajani Dinavahi, Yan Sun, Weizhi Zhao, Faith Galderisi, Aditi Mehta

Blood (2021) 138 (Supplement 1): 887.

https://doi.org/10.1182/blood-2021-147226

Published: 2021

Journal Articles

JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID)

Blood (2021) 138 (Supplement 1): 554.

https://doi.org/10.1182/blood-2021-153074

Published: 2021

Journal Articles

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Susan Prockop, Kris Michael Mahadeo, Amer Beitinjaneh, Sylvain Choquet, Patrick Stiff, Ran Reshef, Gowri Satyanarayana, Saurabh Dahiya, Hema Parmar, Wei Ye, Laurence Gamelin, Rajani Dinavahi

Blood (2021) 138 (Supplement 1): 301.

https://doi.org/10.1182/blood-2021-147274

Published: 2021

Journal Articles

CD4 + T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation

Blood (2021) 137 (6): 848–855.

https://doi.org/10.1182/blood.2020007905

Published: 2021

Includes: Supplemental data

Journal Articles

Efficacy of Remestemcel-L Treatment in Steroid Refractory Acute Graft-Versus-Host Disease in Children: An Aggregate Analysis

Joanne Kurtzberg, MD, Paul J Martin, MD, Susan Prockop, MD, Elizabeth Burke, ANP, Karen Segal, PhD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-138593

Published: 2020

Journal Articles

Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136341

Published: 2020

Journal Articles

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Blood (2019) 134 (26): 2361–2368.

https://doi.org/10.1182/blood.2019001641

Published: 2019

Includes: Supplemental data

Journal Articles

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Susan Prockop, MD, Ran Reshef, MDMSc, Donald E. Tsai, MD PhD, Nancy Bunin, MD, Rolla Abu-Arja, MD, Kris Michael Mahadeo, MD, Wen-Kai Weng, MD PhD, Koen Van Besien, MD PhD, David Loeb, MD PhD, Sunita Dwivedy Nasta, MD, Eneida R. Nemecek, MDMBA,MSc, Minoti Hiremath, MBBS, PhD, Susan Yue, MD, Yan Sun, PhD, Willis Navarro, MD, Sarah Nikiforow, MD PhD

Blood (2019) 134 (Supplement_1): 4071.

https://doi.org/10.1182/blood-2019-124904

Published: 2019

Journal Articles

Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL

Vanessa Fabrizio, MD, Farid Boulad, MD, Maria I. Cancio, MD, Meghan A. Higman, MD PhD, Steven P. Margossian, MD PhD, Audrey Mauguen, PhD, Susan Prockop, MD, Andromachi Scaradavou, MD, Niketa C. Shah, MD, Barbara Spitzer, MD, Nick Yeager, Nancy A. Kernan, Richard O'Reilly, MD, Jaap Jan Boelens, MD PhD, Kevin J. Curran, MD

Blood (2019) 134 (Supplement_1): 4582.

https://doi.org/10.1182/blood-2019-121767

Published: 2019

Journal Articles

A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV + PTLD) after Failure of Rituximab or Rituximab and Chemotherapy

Susan Prockop, MD, Minoti Hiremath, MBBS, PhD, Wei Ye, PhD, Laurence Gamelin, MD, Willis Navarro, MD, Kris Michael Mahadeo, MD

Blood (2019) 134 (Supplement_1): 5326.

https://doi.org/10.1182/blood-2019-129277

Published: 2019

Journal Articles

Adoptive Therapy with EBV-Specific T Cells for Treatment of CNS EBV Post-Transplant Lymphoproliferative Disease Arising after Hematopoietic Stem Cell Transplant or Solid Organ Transplant

Susan Prockop, MD, Stephanie Suser, Ekaterina Doubrovina, MD PhD, Hugo R. Castro-Malaspina, MD, Esperanza B. Papadopoulos, MD, Craig S. Sauter, MD, James W. Young, MD, Victoria Szenes, PNP, Alison Slocum, MA, Karim Baroudy, MS, Richard J. O'Reilly, MD

Blood (2018) 132 (Supplement 1): 4590.

https://doi.org/10.1182/blood-2018-99-120133

Published: 2018

Journal Articles

Dual-Sensitized T-Cells Responding to EBV Blcl and Either CMVpp65 or WT-1 Peptide Pools Have Distinct or Shared HLA Restrictions That May Depend on the Presenting HLA Alleles

Ekaterina Doubrovina, MD PhD, Aisha N. Hasan, MD, Susan Prockop, MD, Karim Baroudy, MS, Richard O'Reilly, MD

Blood (2018) 132 (Supplement 1): 4596.

https://doi.org/10.1182/blood-2018-99-119001

Published: 2018

Journal Articles

Adoptive T-Cell Therapy with 3 rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant

Susan Prockop, MD, Ekaterina Doubrovina, MD PhD, Irene Rodriguez-Sanchez, Aisha N. Hasan, MD, Juliet Barker, MBBS, H.R. Castro-Malaspina, MD, Parastoo B. Dahi, MD, Sergio A. Giralt, MD, Boglarka Gyurkocza, MD, Nancy A. Kernan, MD, Guenther Koehne, MDPhD, Esperanza B. Papadopoulos, MD, Doris Ponce, MD, Craig S. Sauter, MD, Virginia Escobedo, RN, Victoria Szenes, PNP, Karim Baroudy, BS, Alison Slocum, MA, Richard J. O'Reilly, MD

Blood (2017) 130 (Supplement 1): 747.

https://doi.org/10.1182/blood.V130.Suppl_1.747.747

Published: 2017

Journal Articles

Brentuximab Vedotin Plus Bendamustine Is an Effective Salvage Regimen for Pediatric Patients with Relapsed Hodgkin Lymphoma

Nitya Gulati, MBBS, Farid Boulad, MD, Maria I. Cancio, MD, Kevin J. Curran, MD, Carolyn Jackson, Nancy Kernan, MD, Andrew L. Kung, MD PhD, Richard O'Reilly, MD, Susan Prockop, MD, Kavitha Ramaswamy, MD, Andromachi Scaradavou, MD, Barbara Spitzer, Neerav Shukla, MD, Peter G. Steinherz, MD, Christopher Forlenza

Blood (2017) 130 (Supplement 1): 5172.

https://doi.org/10.1182/blood.V130.Suppl_1.5172.5172

Published: 2017

NARROW

Long-Term Outcome of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) Using an Enhancer-Deleted Self-Inactivating Gammaretroviral Vector

Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein-Barr Virus-Positive (EBV + ) Leiomyosarcomas (LMS)

Lentiviral Gene Therapy with Low Dose Conditioning for X-Linked SCID Results in Complete Immune Reconstitution and No Evidence of Clonal Expansion

Early intestinal microbial features are associated with CD4 T-cell recovery after allogeneic hematopoietic transplant

Overall Survival By Best Overall Response with Tabelecleucel in Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ or Allogeneic Hematopoietic Cell Transplant

JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment, Donor Myeloid Chimerism, and Production of Donor Derived Naïve Lymphocytes in Patients with Severe Combined Immunodeficiency (SCID)

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

CD4 + T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation

Efficacy of Remestemcel-L Treatment in Steroid Refractory Acute Graft-Versus-Host Disease in Children: An Aggregate Analysis

Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Long-Term Outcomes of Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) Following Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplants (HCT) Treated with Tabelecleucel on an Expanded Access Program

Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL

A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease (EBV + PTLD) after Failure of Rituximab or Rituximab and Chemotherapy

Adoptive Therapy with EBV-Specific T Cells for Treatment of CNS EBV Post-Transplant Lymphoproliferative Disease Arising after Hematopoietic Stem Cell Transplant or Solid Organ Transplant

Dual-Sensitized T-Cells Responding to EBV Blcl and Either CMVpp65 or WT-1 Peptide Pools Have Distinct or Shared HLA Restrictions That May Depend on the Presenting HLA Alleles

Adoptive T-Cell Therapy with 3 rd Party CMV-pp65-Specific CTLs for CMV Viremia and Disease Arising after Allogeneic Hematopoietic Stem Cell Transplant

Brentuximab Vedotin Plus Bendamustine Is an Effective Salvage Regimen for Pediatric Patients with Relapsed Hodgkin Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only